Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $161.22M
• Dividend Yield: N/A
• Average Volume (3M): 285.43K
• Price to Earnings (P/E): 0.7
• Beta (1Y): 0.44
• Revenue Growth: -99.07%
• EPS Growth: -10347.56%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.05
• Shares Outstanding: 24,726,694
• 10 Day Avg. Volume: 468,712
• 30 Day Avg. Volume: 285,426
• PEG Ratio: <0.01
• Price to Book (P/B): 0.58
• Price to Sales (P/S): 1.56
• P/FCF Ratio: -0.81
• Enterprise Value/Market Cap: 0.02
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 0.10
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $36.33
• Price Target Upside: 457.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -3.53
• Revenue Forecast (FY): $7.57M

• Rating: 52 Neutral
• Price Target: $7.00 ▲(7.36% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

Overall score is held back primarily by weak financial performance (large losses, steep TTM revenue drop, and heavy cash burn). Technicals are constructive but overbought, while corporate updates and stated cash runway provide some support; valuation remains a headwind due to negative earnings and no dividend.

Positive Factors

Proprietary ARCUS platform

A proprietary genome‑editing platform provides durable competitive advantage: ARCUS enables multiple in‑vivo programs and external collaborations, allowing the company to leverage one technology across indications, reduce per‑program R&D rebuild, and scale scientific expertise over time.

Multi-year cash runway

A disclosed cash balance and explicit runway to 2028 materially lowers near‑term financing risk, permitting execution of clinical milestones and data generation without immediate dilution; that stability supports sustained development and value realization over multiple years.

Collaborations and milestone payments

Active partnerships that generate milestone and collaboration payments provide non‑dilutive funding and external validation of ARCUS utility. These arrangements diversify funding sources, accelerate development via shared expertise, and create recurring catalyst opportunities tied to partner progress.

Negative Factors

High cash burn and negative FCF

Persistent large negative operating and free cash flow erodes runway absent additional financing; over months this increases dilution risk or forces partnership/asset sales. High burn means management must execute milestones precisely to avoid costly capital raises that dilute shareholders.

Volatile and declining revenues

Sharp revenue decline and swing to large losses indicate the company's top‑line is variable and tied to one‑off collaboration timing. This volatility undermines predictability, complicates planning, and increases reliance on uncertain milestone timings to restore durable profitability.

Clinical‑stage, no commercial products

Being clinical‑stage means revenue depends on trial success and partner milestones rather than recurring product sales; development failures or regulatory delays are binary risks that can stall cash inflows for extended periods, amplifying execution and financing uncertainty.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences primarily generates revenue through collaboration and licensing arrangements tied to its ARCUS genome editing platform rather than through commercial product sales (as it is a clinical-stage company). Key revenue streams typically include: (1) upfront payments received upon entering strategic collaborations or licensing deals; (2) research and development (R&D) service or cost-reimbursement revenue where partners fund or share development activities; (3) milestone payments earned when partnered programs achieve predefined development, regulatory, or commercialization events; and (4) potential royalties on net sales if partnered products reach the market. The magnitude and timing of these revenues depend on executing new partnerships and achieving contractual milestones, which can make revenue inherently variable from period to period. Specific current partners, deal terms, and product-level commercial revenue are null.

Precision BioSciences Financial Statement Overview

Summary

Financials are pressured by sharp TTM revenue decline and a return to large losses, alongside materially negative operating and free cash flow (significant cash burn). The main offset is a relatively supportive balance sheet with very low debt versus equity, but funding runway/execution remain key swing factors.

Income Statement

Results show very high volatility and weak profitability. Revenue in TTM (Trailing-Twelve-Months) fell sharply to $34.3M from $68.7M in 2024, and gross profit turned negative, pointing to unfavorable cost dynamics. While 2024 posted positive net income ($7.2M) and solid gross profitability, the business reverted to a large loss in TTM (net loss of ~$45.7M) with deeply negative operating profitability, indicating earnings are not yet durable.

Balance Sheet

Balance sheet looks relatively supportive for an early-stage biotech. Total debt is very low in TTM (~$1.5M) against stockholders’ equity of ~$92.2M, suggesting limited balance-sheet leverage today. That said, returns on equity are negative in TTM, reflecting ongoing losses, and equity has fluctuated over time, which can be pressured further if cash burn continues.

Cash Flow

Cash generation remains a key weakness. Operating cash flow is materially negative across all periods, including TTM at about -$65.8M, with free cash flow also deeply negative (about -$66.2M) and worsening versus the prior period. While free cash flow and net income move together (both negative in TTM), the scale of cash burn increases financing risk and reduces flexibility without additional capital.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	34.26M	68.70M	48.73M	25.10M	115.53M
Gross Profit	31.51M	68.70M	48.73M	25.10M	115.53M
EBITDA	-49.40M	13.53M	-32.04M	-62.79M	-20.27M
Net Income	-46.61M	7.17M	-61.32M	-111.64M	-30.60M
Balance Sheet
Total Assets	154.42M	136.39M	159.78M	238.17M	211.50M
Cash, Cash Equivalents and Short-Term Investments	115.58M	86.31M	116.68M	189.58M	143.66M
Total Debt	28.81M	30.05M	31.27M	24.96M	9.11M
Total Liabilities	62.17M	80.00M	140.92M	177.74M	120.33M
Stockholders Equity	92.25M	56.39M	18.86M	60.43M	91.17M
Cash Flow
Free Cash Flow	-65.93M	-58.70M	-86.39M	-49.07M	-16.66M
Operating Cash Flow	-65.84M	-58.45M	-84.11M	-45.75M	-10.85M
Investing Cash Flow	-634.00K	-215.00K	5.83M	-3.32M	-5.80M
Financing Cash Flow	95.16M	50.45M	5.39M	94.98M	70.52M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 6.52 is above the 20-day moving average (MA) of 5.14, above the 50-day MA of 4.44, and above the 200-day MA of 4.98, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 70.56 is Negative, neither overbought nor oversold. The STOCH value of 72.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DTIL	52 Neutral	$161.22M	0.69	-96.96%	―	-99.07%	-10347.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$64.32M	-1.19	-53.71%	―	―	21.17%
CTMX	46 Neutral	$757.33M	-6.84	-19.77%	―	-10.26%	144.62%
ACET	45 Neutral	$66.41M	-0.48	-77.90%	―	―	25.89%
IMA	42 Neutral	$63.64M	-0.74	-33.05%	―	-100.00%	45.48%

Precision BioSciences Corporate Events

Precision BioSciences Highlights PBGENE-DMD Program and Trial

On March 17, 2026, Precision BioSciences hosted a live investor and key opinion leader webcast to provide an update on its PBGENE-DMD gene-editing program and the FUNCTION-DMD Phase 1/2 trial for Duchenne muscular dystrophy. Pediatric neurologist Aravindhan Veerapandiyan and patient advocate Pat Furlong joined company management to discuss the unmet need, current DMD treatment landscape, and the planned clinical strategy, positioning PBGENE-DMD as a potentially differentiated approach aimed at restoring muscle function and informing investors about near-term development milestones across the DMD franchise.

The most recent analyst rating on (DTIL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Highlights 2026 Gene Editing Priorities

On January 12, 2026, Precision BioSciences outlined its 2026 strategic priorities centered on advancing its two lead ARCUS-based in vivo gene editing programs—PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy—while emphasizing a solid cash position of approximately $137 million as of December 31, 2025, which it expects will support key data milestones through 2028. The company reported encouraging safety and antiviral activity data from multiple dosing cohorts in its global Phase 1/2a ELIMINATE-B trial for PBGENE-HBV, with plans to complete dosing in Cohorts 3, 4, and 5, select an optimal regimen to enable stopping nucleos(t)ide analog treatment, and move into trial expansion, while also preparing to initiate patient dosing in the Phase 1/2 FUNCTION-DMD trial in early 2026 and deliver initial Duchenne data by year-end; additional value drivers include partnered programs ECUR-506 and azer-cel, which have reached significant regulatory and clinical milestones and triggered an $8 million payment in late 2025, underscoring Precision’s strengthened financial and strategic position in the gene editing field.

The most recent analyst rating on (DTIL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.